skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Executive Summary

Quality data will be focus of ‘extra advice’ offered by European Medicines Agency’s pilot, which will suggest directions for sponsors’ next steps but stop short of formal data evaluation.

 

The European Medicines Agency will start offering tailored scientific advice for a limited number of biosimilars as part of a pilot to be launched in February next year.


The pilot has been devised in response to a demand from companies who are looking "for this extra advice, specifically for biosimilars," the EMA told the Pink Sheet. The US Food and Drug Administration already offers biosimilar sponsors a similar possibility. (Also see "Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan" - Pink Sheet, 28 Sep, 2016.)


The EMA pilot will specifically deal with scientific advice relating to quality aspects. According to the agency, companies will be able to provide quality data and get extended advice that will help them plan future product development and prepare better for a marketing authorization submission.


EMA does not see this as advanced data assessment, as companies will only get additional advice to help them better plan their product's continuing development for next steps, such as those pertaining to quality, non-clinical, clinical aspects, the spokesperson added.


The tailored approach will be different from the EMA's current scientific advice procedure, as this does not involve a formal assessment of data. Under the tailored approach, advice will be given on the basis of the data submitted by companies. Specifically, the EMA will carry out an in-depth review of the quality, analytical and functional data available, which will allow for more tailored recommendations on the studies/tests that should be carried out in the next step of the development. This will allow companies to make a more informed decision on their development strategy once sufficient quality data has been accumulated.

 

Resource Intensive


Providing such tailored scientific advice will be resource intensive for the assessors and members of the EMA's scientific advice working party (SAWP). "This pilot should help us to judge how much additional effort is required and where,” the agency spokesperson said.


The fee will be the standard fee for a scientific advice procedure including quality, non-clinical and clinical questions.


To ensure that the agency is not overburdened with requests, the pilot is planned to run until six scientific advice requests have been completed, with no more than one scientific advice request accepted per month. The pilot will help the agency test the added value and feasibility of providing such a service on a permanent basis in the future. "We would explore the experience of both parties (industry and regulators) before deciding to continue/modify/not use the approach," the EMA spokesperson said.


The pilot will be open to all companies seeking scientific advice for the development of any type of biosimilar. Companies wanting to participate in the pilot will have a pre-submission meeting, during which the suitability of their data package will be reviewed. The SAWP will need an extra month on top of the normal scientific advice timelines to review the requests accepted in the pilot.


The EMA currently has 17 biosimilar products under evaluation. (Also see "Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU" - Pink Sheet, 21 Dec, 2016.)


From the editors of Scrip Regulatory Affairs. 

 

Read also

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Pink Sheet: global policy and regulatory coverage

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

  • Scrip: industry news and insights

    Hong Kong Takes On Nasdaq For China Biotech IPOs

    ByBrian Yang

    Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.

    Topics Policy and regulation

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: